Drug Profile
AF 05
Alternative Names: AF-05; AF-5Latest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator Institute of Materia Medica
- Developer Beijing Collab Pharma; Institute of Materia Medica
- Class Sesquiterpenes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Anxiety disorders
Most Recent Events
- 27 Aug 2019 AF 05 is still in phase II for Anxiety disorder in China (Beijing Collab Pharma website, August 2019)
- 01 Mar 2016 Phase-II clinical trials in Anxiety disorders in China (unspecified route)
- 30 Nov 2009 Phase-I clinical trials in Anxiety disorders in China (unspecified route)